Thursday July 25, 2024 8am PT, 11am ET
Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab and High-Throughput Single B Cell Screening
In this webinar, Dr. Shun Zhou explores the revolutionary potential of the genome-edited mouse HUGO-Ab, where endogenous VH and VL genes are replaced by fully human VH and VL genes in situ, enabling the generation of fully human antibody molecules. When combined with microfluidic technology-enhanced single B cell screening, this approach allows for the high-throughput and efficient discovery of antibody drug molecules.
Speaker: Dr. Shun Zhou
Shun Zhou holds a Ph.D. Molecular Biology and Genetics from the Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, and was a Postdoctoral Fellow in the Department of Biomedical Engineering at Tufts University, USA. With over 10 years of research and development experience in molecular biology, cell biology, and genetics, his work has been published in more than 10 articles in journals such as PNAS and Acta Biomaterialia. Currently serving as the R&D Director at Cyagen Bioscience, he has extensive project research experience in gene editing technologies, Gene and Cell therapy drug research technologies, and antibody discovery technologies, participating in several preclinical projects for antibody drugs and gene and cell therapy drugs.
Registration is open!
Note: The webinar platform and registration process is managed by Community Brands.
Their privacy policy is here.
Our selection of On Demand webinars can be viewed here.
Our YouTube channel includes selected webinars as well as recordings of our Symposia on topics such as:
- Computational Antibody Discovery: State of the Art
- Biopharmaceutical Informatics
- Harnessing Cytokines for Cancer Immunotherapy
- Emerging Immunotherapeutics for Ovarian Cancer Symposium
- Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells